Skip to main content
Premium Trial:

Request an Annual Quote

Biotage Inks Distribution, R&D Pacts with MultiSynTech

NEW YORK (GenomeWeb News) — Under two new agreements it has struck with the German company MultiSynTech, Biotage will join the peptide synthesis market, the Swedish biotech firm said today.

Through one agreement, Biotage has acquired distribution rights to all of MultiSynTech's robotic peptide synthesis systems.

The companies also will work together on a development project to design and market a microwave-aided peptide synthesis system, with the goal of increasing the yield and speed of the peptide synthesis process. The system will integrate Biotage's microwave technology with MutiSynTech's robotic synthesizer technology, the firms said. Customers for the system will include university and biopharmaceutical research groups and contract labs.

These agreements will allow Biotage, which also has operations in the US, Japan, the UK, and Germany, to offer parallel synthesis and microwave synthesis.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.